Healio Generalized Myasthenia Gravis: Understanding the Role of FcRn Antagonists
This CME program is designed to enhance neurologists’ understanding and management of generalized myasthenia gravis (gMG). Participants will explore how comprehensive assessment of disease burden can inform clinical decision-making and improve individualized care. The program will also examine the pathophysiology of gMG, emphasizing how this guides treatment selection. The limitations of current standard-of-care therapies will also be explored. Participants will review the latest clinical evidence surrounding neonatal Fc receptor (FcRn) inhibitors, including their role in addressing underlying disease processes and supporting long-term management strategies. By integrating all of these insights, neurologists will be better equipped to optimize patient outcomes and achieve sustained disease control in individuals with gMG.
Cost: Free
View Offer chevron_rightDetails
This CME program is designed to enhance neurologists’ understanding and management of generalized myasthenia gravis (gMG). Participants will explore how comprehensive assessment of disease burden can inform clinical decision-making and improve individualized care. The program will also examine the pathophysiology of gMG, emphasizing how this guides treatment selection. The limitations of current standard-of-care therapies will also be explored. Participants will review the latest clinical evidence surrounding neonatal Fc receptor (FcRn) inhibitors, including their role in addressing underlying disease processes and supporting long-term management strategies. By integrating all of these insights, neurologists will be better equipped to optimize patient outcomes and achieve sustained disease control in individuals with gMG.
Topics Covered
Generalized Myasthenia Gravis
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Recognize how appropriate assessment of disease burden can guide clinical decision-making for patients with gMG.
- Identify how the pathophysiology of gMG informs treatment selection, highlighting the limitations of standard-of-care therapies in addressing disease mechanisms.
- Evaluate the latest clinical data on FcRn inhibitors for the treatment of patients with gMG.
- Assess the role of FcRn inhibitors in long-term management strategies for patients with gMG to improve sustained patient outcomes.
Target Audience
The intended audience for the activities is neurologists involved in the management of patients with gMG.
Additional credit info
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.